Last updated on July 2019

A Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis


Brief description of study

This is a Phase 1b/2, multi-center study in which patients will receive KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks.

The study consists of 2 parts. Part 1, the Phase 1b, is an open-label multiple dose escalation study to evaluate the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus (SLE) with and without nephritis. Part 2, the Phase 2, is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of KZR-616 in patients with active proliferative lupus nephritis (LN).

Clinical Study Identifier: NCT03393013

Find a site near you

Start Over

KZR Research Site

Thousand Oaks, CA United States
  Connect »

KZR Research Site

Upland, CA United States
  Connect »

KZR Research Site

Coral Gables, FL United States
  Connect »

KZR Research Site

Miami, FL United States
  Connect »

KZR Research Site

Orlando, FL United States
  Connect »

KZR Research Site

Palm Harbor, FL United States
  Connect »

KZR Research Site

Tampa, FL United States
  Connect »

KZR Research Site

Great Neck, NY United States
  Connect »

KZR Research Site

Manhasset, NY United States
  Connect »

KZR Research Site

Rochester, NY United States
  Connect »

KZR Research Site

Columbus, OH United States
  Connect »

KZR Research Site

Memphis, TN United States
  Connect »

KZR Research Site

Houston, TX United States
  Connect »

KZR Research Site

Parkville, Australia
  Connect »

KZR Research Site

Barranquilla, Colombia
  Connect »

KZR Research Site

Bucaramanga, Colombia
  Connect »

KZR Research Site

Guadalajara, Mexico
  Connect »

KZR Research Site

Mexico City, Mexico
  Connect »